Last reviewed · How we verify
MER4101
At a glance
| Generic name | MER4101 |
|---|---|
| Also known as | Inactivated Influenza Vaccine with MAS-1 Adjuvant |
| Sponsor | Nova Immunotherapeutics Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) (PHASE1)
- MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |